Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

Home

QDEL

Q

QuidelOrtho Corporation (QDEL)

NMS – Real Time Price. Currency in USD

14.78

-0.82 (-5.26%)

At close: Mar 27, 2026, 4:00 PM EDT

14.75

-0.03 (-0.20%)

After-hours: Mar 27, 2026, 7:49 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer

Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer

SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will report to Brian Blaser, President and Chief Executive Officer, and will lead QuidelOrtho's global legal, compliance and corporate governance functions.

Why Is QuidelOrtho (QDEL) Down 24.5% Since Last Earnings Report?

Why Is QuidelOrtho (QDEL) Down 24.5% Since Last Earnings Report?

QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock?

Rice Hall James Buys QuidelOrtho Stock

Rice Hall James Buys QuidelOrtho Stock

Rice Hall James purchased 574,877 shares of QuidelOrtho stock in the fourth quarter. The quarter-end position value grew by $16.2 million, reflecting both additional shares and price changes.

QuidelOrtho Corp Director Purchases 10k Shares as CFO Retires

QuidelOrtho Corp Director Purchases 10k Shares as CFO Retires

A board director at QuidelOrtho Corp. acquired 10,000 common shares on Feb. 13, 2026, at an average price of around $23.96 per share, totaling ~$240,000. All shares were acquired for direct ownership; indirect holdings via UGMA accounts and Birchview Fund, LLC, remain unchanged at 54,775 shares.

Faster Cardiac Answers with High‑Sensitivity Troponin

Faster Cardiac Answers with High‑Sensitivity Troponin

SAN DIEGO, Feb. 19, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 56 of its Science Bytes podcast, featuring Dr. Lindy Carlstrom, Global Medical Affairs Manager for Acute Care. In this episode, Carlstrom and host Josh Casey discuss how high-sensitivity troponin (hs troponin) is transforming early cardiac diagnosis and improving emergency department efficiency.

QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference

QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference

SAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced that members of its management team will present at the Raymond James 47th Annual Institutional Investor Conference. The Company's presentation is scheduled for Tuesday, March 3, 2026, at 1:40 p.m.

QDEL Expands Immunoassay Portfolio Via Lifotronic Supply Agreement

QDEL Expands Immunoassay Portfolio Via Lifotronic Supply Agreement

QuidelOrtho inks Lifotronic supply deal, adding 70+ assays and new analyzer platforms to boost global immunoassay reach and recurring revenue potential.

Videos

No Data

There is no data to display

Press releases

Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer

Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer

SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will report to Brian Blaser, President and Chief Executive Officer, and will lead QuidelOrtho's global legal, compliance and corporate governance functions.

Faster Cardiac Answers with High‑Sensitivity Troponin

Faster Cardiac Answers with High‑Sensitivity Troponin

SAN DIEGO, Feb. 19, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 56 of its Science Bytes podcast, featuring Dr. Lindy Carlstrom, Global Medical Affairs Manager for Acute Care. In this episode, Carlstrom and host Josh Casey discuss how high-sensitivity troponin (hs troponin) is transforming early cardiac diagnosis and improving emergency department efficiency.

QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results

QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results

― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ― ― Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million ― SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the fourth quarter and full-year ended December 28, 2025. "In 2025, we transitioned from COVID-driven volatility to a more durable, diversified diagnostics business," said Brian J.

QuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie® Awards

QuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie® Awards

– First medical device company to receive excellence recognition in accordance with ISO 23592 – Gold Stevie® Award for Customer Service Success – Bronze Stevie® Award for AI & Tech Focused Digital Transformation Team of the Year SAN DIEGO, Feb. 3, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") received the Excellence Services Label for its Customer and Technical Services in EMEA, awarded by the independent association Esprit de Service France, and in accordance with the international standard ISO 23592, a global framework for designing and delivering outstanding customer experiences. QuidelOrtho is the first medical device company to receive this distinction.